此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets

2026年7月3日 更新者:Humanis Saglık Anonim Sirketi

An Open Label, Balanced, Randomized, Single Dose, Three Treatment, Three Sequence, Three Period, Three Way Crossover Oral Bioequivalence Study to Compare Selexipag 400 Microgram Film Coated Tablets Versus Uptravi® (Selexipag) 400 Microgram Film Coated Tablets in Fed Condition.

An open label, randomized, Three treatment, Three sequence, Three period, Three way crossover, single dose oral bioequivalence study to compare Selexipag 400 microgram film coated tablets versus Uptravi® (selexipag) 400 microgram film coated tablets in fed condition.

研究概览

研究类型

介入性

注册 (实际的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Gujarat
      • Ahmedabad、Gujarat、印度、380 015
        • Veeda Clinical Research Ltd.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人

接受健康志愿者

是的

描述

Inclusion Criteria:

  • Participants aged between 18 to 55 years (both inclusive).
  • Participants' weight within normal range according to normal values for Body Mass Index (between 18.50 to 30.00 kg/m2) (both inclusive) with minimum of 45 kg weight.
  • Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
  • Participants having clinically acceptable 12-lead electrocardiogram (ECG).
  • Participants having clinically acceptable chest X-Ray (PA view), if taken.
  • Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
  • Participants having negative urine alcohol test / breath alcohol test.
  • Non-smoker.
  • Participants willing to adhere to the protocol requirements and to provide written informed consent.
  • For Male Participants: Participants willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
  • For Female Participants: Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam or Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
  • Participants having negative urine pregnancy test at screening and negative serum beta-hCG pregnancy test on admission day of period 01 (only for female Participants).

Exclusion Criteria:

  • Hypersensitivity to Selexipag or ondansetron, paracetamol, or related class of drugs or any of its excipients.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
  • Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
  • Presence of alcoholism or drug abuse.
  • History or presence of asthma, urticaria or other significant allergic reactions.
  • History or presence of significant gastric and/or duodenal ulceration.
  • History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
  • History or presence of serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs).
  • History or presence of cancer or basal or squamous cell carcinoma.
  • Difficulty with donating blood.
  • Difficulty in swallowing solids dosage form like tablets or capsules.
  • Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
  • Major illness within past 3 months.
  • Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
  • Consumption of xanthine-containing foods or beverages (like chocolate, tea, coffee or cola drinks), tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
  • Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
  • Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
  • History or presence of significant easy bruising or bleeding.
  • History or presence of significant recent trauma.
  • Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
  • Female Participants who are currently breast feeding.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:其他
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Selexipag film coated tablets (T1)
Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets
实验性的:Selexipag film coated tablets (T2)
Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets
有源比较器:Uptravi® (selexipag) film coated tablets
Uptravi® (selexipag) 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Selexipag 400 microgram film coated tablets
1 tablet of Uptravi® (selexipag) 400 microgram film coated tablets

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum concentration obtained (Cmax)
大体时间:20 hours
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data Cmax
20 hours
AUC from time 0 to last collection time (AUC0 - t)
大体时间:20 hours
two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC
20 hours

次要结果测量

结果测量
措施说明
大体时间
Time to reach maximum concentration Cmax (Tmax)
大体时间:20 hours
Descriptive Statistics
20 hours
Area Under the Curve from time zero to time infinite (AUC0-infinite)
大体时间:20 hours
Descriptive Statistics
20 hours

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年4月8日

初级完成 (实际的)

2026年6月16日

研究完成 (实际的)

2026年6月22日

研究注册日期

首次提交

2026年7月3日

首先提交符合 QC 标准的

2026年7月3日

首次发布 (实际的)

2026年7月9日

研究记录更新

最后更新发布 (实际的)

2026年7月9日

上次提交的符合 QC 标准的更新

2026年7月3日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • 25-VIN-0711

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅